Patents Assigned to Endo Pharmaceuticals Solutions Inc.
-
Publication number: 20210161994Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.Type: ApplicationFiled: February 10, 2021Publication date: June 3, 2021Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Publication number: 20200046806Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: ApplicationFiled: August 22, 2019Publication date: February 13, 2020Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stefanie Decker
-
Publication number: 20190388500Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.Type: ApplicationFiled: September 9, 2019Publication date: December 26, 2019Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Stephanie Decker
-
Publication number: 20190365847Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues car organs.Type: ApplicationFiled: June 28, 2019Publication date: December 5, 2019Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Publication number: 20170100461Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.Type: ApplicationFiled: August 24, 2016Publication date: April 13, 2017Applicant: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: Petr Kuzma, Stefanie Decker
-
Publication number: 20170049850Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.Type: ApplicationFiled: August 24, 2016Publication date: February 23, 2017Applicant: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: PETR KUZMA, STEFANIE DECKER
-
Publication number: 20160193280Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).Type: ApplicationFiled: November 9, 2015Publication date: July 7, 2016Applicant: Endo Pharmaceuticals Solutions Inc.Inventor: Petr KUZMA
-
Publication number: 20150283201Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.Type: ApplicationFiled: November 6, 2014Publication date: October 8, 2015Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Patent number: 9120249Abstract: Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm2 or greater.Type: GrantFiled: April 25, 2008Date of Patent: September 1, 2015Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: Petr Kuzma, Stephanie Decker, Harry Quandt
-
Publication number: 20150190413Abstract: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.Type: ApplicationFiled: March 20, 2015Publication date: July 9, 2015Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: John CHABER, Petr KUZMA, Agis KYDONIEUS
-
Patent number: 9072786Abstract: Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.Type: GrantFiled: May 20, 2013Date of Patent: July 7, 2015Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.Inventors: Petr Kuzma, Stefanie Decker, Harry Quandt
-
Publication number: 20140349936Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).Type: ApplicationFiled: August 11, 2014Publication date: November 27, 2014Applicant: Endo Pharmaceuticals Solutions Inc.Inventor: Petr KUZMA
-
Patent number: 8784865Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.Type: GrantFiled: May 13, 2013Date of Patent: July 22, 2014Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Petr Kuzma, Harry Quandt
-
Publication number: 20140135684Abstract: This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.Type: ApplicationFiled: January 20, 2014Publication date: May 15, 2014Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Sheng-hung Kuo, Petr Kuzma
-
Patent number: 8658195Abstract: This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.Type: GrantFiled: July 26, 2013Date of Patent: February 25, 2014Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Sheng-hung Kuo, Petr Kuzma
-
Patent number: 8618127Abstract: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chloro-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindolinone.Type: GrantFiled: June 6, 2012Date of Patent: December 31, 2013Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: John J. Murphy, Kay Jorgenson D'Orlando
-
Patent number: 8604086Abstract: The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 26, 2009Date of Patent: December 10, 2013Assignee: Endo Pharmaceuticals Solutions Inc.Inventor: Albert T. Profy
-
Publication number: 20130310740Abstract: This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.Type: ApplicationFiled: July 26, 2013Publication date: November 21, 2013Applicant: Endo Pharmaceuticals Solutions Inc.Inventors: Sheng-hung KUO, Petr Kuzma
-
Patent number: D698919Type: GrantFiled: October 24, 2012Date of Patent: February 4, 2014Assignee: Endo Pharmaceuticals Solutions Inc.Inventors: Alexander Schwarz, Richard Caizza
-
Patent number: D708324Type: GrantFiled: October 24, 2012Date of Patent: July 1, 2014Assignee: Endo Pharmaceuticals Solutions, Inc.Inventors: Alexander Schwarz, Richard Caizza